Concurrent Once-daily Versus twice-daily Radiation Therapy

Official Title

A 2-arm randomized controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiation therapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status.

Summary:

Type of design
This is a multicentre randomized phase III trial.
Patients are randomized to one of two treatment arms with 1:1 randomization:
Patients will be randomly allocated to treatment, using a minimization procedure.

Patients studied
Histologically or cytologically confirmed SCLC with limited disease (Veterans Administration Lung Cancer
Study Group) ie patients whose disease can be encompassed within a radical radiation portal. No pleural or
pericardial effusions proven to be malignant. RT target volume acceptable by the local radiotherapist. ECOG
performance status 0-2.

Concurrent Once-daily versus twice-daily
Radiation therapy: A 2-arm randomized controlled trial of
concurrent chemo-radiotherapy comparing twice-daily
and once-daily radiation therapy schedules in patients with
limited stage small cell lung cancer (SCLC) and good
performance status.

Trial Description

Trial interventions
Control Arm:
Four to six cycles of Cisplatin 25 mg/m2 iv D1-3 or 75 mg/m2 D1 Etoposide 100 mg/m2 iv D1-3 with
concurrent BD radiotherapy 45Gy in 30 twice-daily fractions over 3 weeks, 5 days per week
from day 22 of cycle 1

Experimental Arm:
Four to six cycles of Cisplatin 25 mg/m2 iv D1-3 or 75 mg/m2 D1 Etoposide 100 mg/m2 iv D1-3 with
concurrent OD radiotherapy 66Gy in 33 daily fractions over 6.5 weeks, 5 days per week
from day 22 of cycle 1

Outcome measures
Primary end-point
• Overall survival
Secondary end points
• Local progression-free survival
• Metastasis-free survival
• CTCAE v3.0 toxicity
• Chemotherapy dose intensity
• Radiotherapy dose intensity

Duration of assessment
Patients will be assessed prior to each cycle of chemotherapy and at 4 weeks after the final cycle. Follow-up
will be at 3 monthly intervals for 12 months and six monthly thereafter until death. Post treatment CT scans
thorax and abdomen will be done within 4 weeks of cycle 4 (even if 6 cycles are given) and 6 months after
randomization.

Data collection
Data will be recorded on Case Report Forms (CRFs), a copy should be sent to the Christie Hospital CTU for data
entry and a copy kept at the local centre.

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society